SCHEMBL23851073

SCHEMBL23851073

Nc1cc(Br)c(Cl)cc1N1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.53
KDM4E B2RXH2 4/20 0.53
LMNA P02545 3/20 0.53
HTT P42858 3/20 0.53
POLB P06746 3/20 0.51
MAPT P10636 5/20 0.47
GAA P10253 5/20 0.47
L3MBTL1 Q9Y468 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
TDP1 Q9NUW8 3/20 0.47
S100B P04271 2/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 2/20 0.44
APAF1 O14727 1/20 0.44
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31587945 1.00 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAHTTPOLB
SCHEMBL29669393 0.98 ALDH1A1 (0.50) ALDH1A1KDM4ELMNAHTTPOLB
SCHEMBL23850842 0.85 ALDH1A1 (0.59) ALDH1A1KDM4ELMNAHTTPOLB
SCHEMBL31588087 0.75 ALDH1A1 (0.49) ALDH1A1KDM4ELMNAHTTPOLB
SCHEMBL23850917 0.75 ALDH1A1 (0.49) ALDH1A1KDM4ELMNAHTTPOLB
SCHEMBL31586562 0.73 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAHTTPOLB
SCHEMBL23850711 0.72 ALDH1A1 (0.65) ALDH1A1LMNAHTTPOLBMAPT
SCHEMBL23851388 0.72 ALDH1A1 (0.49) ALDH1A1KDM4ELMNAHTTPOLB
SCHEMBL31588217 0.72 ALDH1A1 (0.65) ALDH1A1LMNAHTTPOLBMAPT
SCHEMBL28854051 0.72 ALDH1A1 (0.52) ALDH1A1KDM4ELMNAHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
EP-3883650-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2021-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 ALDH1A1 2613/4885KDM4E 2853/4885LMNA 2596/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR ALDH1A1 276/4885KDM4E 4372/4885LMNA 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.